The ability of vitamin K supplementation to slow calcification of blood vessels in calciphylaxis is not well-studied. Warfarin, a vitamin K antagonist discussed above, should be discontinued if possible.
The effectiveness of vitamin K supplementation in hindering arterial hardening in calciphylaxis has not been extensively investigated. Warfarin, a vitamin K inhibitor previously discussed, should be stopped if feasible.